
Ribo Submits European Clinical Trial Application for a Novel Dual Targeting siRNA SR122 for Mixed and Severe Dyslipidemia, Further Strengthening Its Footprint in the Area of Lipid Disorder
November 10, 2026 – Suzhou, China and Mölndal, Sweden Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB























































